• Halazone and Sodium Current Inactivation in Frog Nerves

  2026-08-12

  The reference study compared Halazone with several chemically selective reagents in voltage-clamped frog nerve fibers and found that Halazone and hypochlorous acid strongly disrupted sodium-current inactivation. The results challenged a methionine-centered explanation and instead supported membrane lipid modification as a tentative mechanism, while highlighting the limits of translating ex vivo neurophysiology into antimicrobial or clinical conclusions.

• EZ Cap EGFP mRNA 5-moUTP: Workflow Guide

  2026-08-12

  Build reproducible reporter, translation, viability, and delivery assays with a Cap1-capped enhanced green fluorescent protein mRNA. This workflow also shows how EGFP benchmarking can de-risk cell-targeted lipid nanoparticle designs inspired by recent spinal cord injury research.

• rTMS, GABAergic Signaling, and Amyloid Clearance

  2026-08-11

  A 2025 Cell Proliferation study identifies a potential mechanism by which repetitive transcranial magnetic stimulation improves cognition in 5xFAD mice: activation of GABAergic neurons increases Cx3cl1 signaling and enhances microglial interaction through Cx3cr1. The findings connect neuromodulation with amyloid clearance and neuroinflammation, while also highlighting the need for parameter-controlled validation in additional models and human studies.

• FLOT1–FOSL2–EphA2 Axis in Alzheimer’s Neuroinflammation

  2026-08-11

  The reference study identifies a FLOT1–FOSL2–EphA2 signaling axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in an APP/PS1 model of Alzheimer’s disease. Its integrated molecular, histological, and behavioral evidence suggests that interrupting this pathway can reduce neuroinflammation and improve spatial memory, while also defining important boundaries for translating peptide-based cell assays to in vivo disease models.

• Potassium Iodide Workflows for Thyroid Research

  2026-08-10

  Build reproducible KI experiments for iodide uptake, thyroid hormone synthesis, and research models of radioactive iodine thyroid blocking. The article also shows how the reference study’s sequential-delivery logic can improve assay design without overstating Potassium Iodide’s role in immunotherapy.

• Methotrexate Workflows for Immunology Research

  2026-08-09

  Build more interpretable Methotrexate assays by aligning DHFR inhibition, intracellular polyglutamates, cell-cycle timing, and inflammatory readouts. This guide combines practical dosing and troubleshooting with a biomimetic chromatography strategy for evaluating membrane-partitioning questions.

• RG108: From DNMT Assay to In Vivo Design

  2026-08-08

  RG108 is a non-nucleosidic DNA methyltransferase inhibitor whose value depends on interpreting biochemical potency alongside cellular methylation dynamics and pharmacokinetics. This guide connects assay design, epigenetic gene regulation modulation, and translational decision-making without treating one IC50 as universal.

• Prednisone Workflows for Immunology Research

  2026-08-07

  Build reproducible lymphocyte assays around Prednisone’s linked effects on G1 arrest, IL-2 signaling, and apoptosis. This guide also shows how LC–MS/MS-inspired exposure checks can strengthen immunology and neurodegeneration workflows without overextending the evidence.

• DiscoveryProbe™ Metabolism-related Compound Library: Technic

  2026-08-07

  The DiscoveryProbe™ Metabolism-related Compound Library (SKU L1032) provides a rigorously validated set of 493 bioactive small molecules for targeted metabolism research, supporting high-throughput screening and pathway analysis. It is optimized for in vitro and ex vivo workflows but is not suitable for diagnostic or clinical use.

• LY-411575: Strategic Gamma-Secretase Inhibition for Translat

  2026-08-06

  Explore how LY-411575 empowers a new era in Alzheimer’s and cancer research by enabling precise modulation of amyloid beta and Notch signaling. This article blends mechanistic insight, competitive context, and translational strategy, referencing breakthrough evidence and practical workflow guidance to help researchers navigate the complexities of γ-secretase inhibition.

• AI-Driven Discovery of Senolytics: Insights for Senescence R

  2026-08-06

  The referenced Nature Communications study introduces a machine learning pipeline to identify new senolytic compounds, addressing the challenge of selectively eliminating senescent cells. This approach reduces drug discovery costs and reveals novel candidates, setting a precedent for future research into aging and age-related diseases.

• E-64d in Translational Research: Mechanistic Insight to Stra

  2026-08-05

  This thought-leadership article explores the mechanistic utility and strategic deployment of E-64d—a membrane-permeable cysteine protease inhibitor—across regulated cell death research, with a focus on translational models in oncology, neuroscience, and functional genomics. By synthesizing recent advances in high-resolution death-rate analytics and emerging cell death modalities, we provide actionable guidance for researchers seeking to harness E-64d for both hypothesis-driven discovery and workflow optimization. The narrative integrates evidence from functional genomic screens, positions APExBIO's E-64d as a pivotal tool, and critically examines the evolving landscape and future frontiers of cysteine protease inhibition.

• Cytochalasin B: Precision Tools for Translational Cytoskelet

  2026-08-05

  Explore how Cytochalasin B (NSC 107658) empowers advanced translational research by enabling mechanistic dissection of actin-dependent pathways in cell division, motility, and host-pathogen interactions. This thought-leadership article connects mechanistic insights with actionable protocol guidance, benchmarking APExBIO’s Cytochalasin B against current landscape tools and highlighting its unique value for translational scientists.

• DiscoveryProbe™ Metabolism-related Compound Library: Technic

  2026-08-04

  The DiscoveryProbe™ Metabolism-related Compound Library addresses workflow bottlenecks in in vitro and ex vivo metabolism research by providing 493 quality-controlled, cell-permeable small molecules targeting key metabolic processes. It is best suited for enzyme inhibition/activation assays, pathway studies, and high-throughput screening, but is not intended for diagnostic, medical, or in vivo use.

• SARS-CoV-2 Nucleocapsid Protein Suppresses GADD34-IRF3 Immun

  2026-08-04

  This study uncovers a mechanism by which the SARS-CoV-2 nucleocapsid protein disrupts the GADD34-mediated innate immune pathway. By sequestering GADD34 mRNA into atypical stress granule foci, viral N protein impairs IRF3 nuclear translocation, weakening interferon responses and facilitating viral replication.

15426 records 1/1029 page Next 12345 下5页 Last page